

Luca G G Guidotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2493005/publications.pdf>

Version: 2024-02-01

109
papers

14,958
citations

17405

63
h-index

30010

103
g-index

112
all docs

112
docs citations

112
times ranked

12151
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunobiology and pathogenesis of hepatitis B virus infection. <i>Nature Reviews Immunology</i> , 2022, 22, 19-32.	10.6	199
2	COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. <i>Molecular Therapy</i> , 2022, 30, 311-326.	3.7	54
3	Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. <i>Science Immunology</i> , 2022, 7, .	5.6	61
4	Group 1 ILCs regulate T cell-mediated liver immunopathology by controlling local IL-2 availability. <i>Science Immunology</i> , 2022, 7, eabi6112.	5.6	18
5	Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?. <i>Hepatology</i> , 2022, 76, 300-302.	3.6	2
6	Developing a cure for chronic hepatitis B requires a fresh approach. <i>Nature</i> , 2022, 603, S49-S49.	13.7	3
7	Arenaviral infection causes bleeding in mice due to reduced serotonin release from platelets. <i>Science Signaling</i> , 2022, 15, eabb0384.	1.6	2
8	Immunological insights in the treatment of chronic hepatitis B. <i>Current Opinion in Immunology</i> , 2022, 77, 102207.	2.4	5
9	Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 73, 128904.	1.0	2
10	Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming. <i>Immunity</i> , 2021, 54, 2089-2100.e8.	6.6	73
11	Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. <i>Science Immunology</i> , 2021, , eabl9929.	5.6	3
12	Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	31
13	Is It Time to Recommend Low-Dose Aspirin Treatment for the Prevention of Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2020, 159, 1988-1990.	0.6	1
14	Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. <i>Nature</i> , 2019, 574, 200-205.	13.7	135
15	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	1.8	341
16	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	3.7	342
17	Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. <i>Journal of Hepatology</i> , 2017, 67, 543-548.	1.8	48
18	Pathogen-specific B cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens. <i>EMBO Molecular Medicine</i> , 2017, 9, 1482-1490.	3.3	15

#	ARTICLE	IF	CITATIONS
19	Microcirculation in the murine liver: a computational fluid dynamic model based on 3D reconstruction from in vivo microscopy. <i>Journal of Biomechanics</i> , 2017, 63, 125-134.	0.9	12
20	<sc>IFN</sc> gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment. <i>EMBO Molecular Medicine</i> , 2016, 8, 155-170.	3.3	29
21	Hepatitis B Virus Immunopathogenesis. <i>Molecular and Translational Medicine</i> , 2016, , 79-93.	0.4	0
22	Inflammatory monocytes hinder antiviral B cell responses. <i>Science Immunology</i> , 2016, 1, .	5.6	93
23	Protective and Pathogenic T Cell Responses to Virus Infections. , 2016, , 318-323.		1
24	Eukaryotic translation initiation factor 6 is a novel regulator of reactive oxygen species-dependent megakaryocyte maturation. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2108-2118.	1.9	13
25	Host-virus interactions in hepatitis B virus infection. <i>Current Opinion in Immunology</i> , 2015, 36, 61-66.	2.4	133
26	Immunosurveillance of the Liver by Intravascular Effector CD8 + T Cells. <i>Cell</i> , 2015, 161, 486-500.	13.5	271
27	Mouse Models of Hepatitis B Virus Pathogenesis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021477.	2.9	23
28	Editorial overview: Viral pathogenesis. <i>Current Opinion in Virology</i> , 2015, 11, v-vii.	2.6	2
29	The COP9 signalosome is a repressor of replicative stress responses and polyploidization in the regenerating liver. <i>Hepatology</i> , 2014, 59, 2331-2343.	3.6	6
30	In Vivo Flow Mapping in Complex Vessel Networks by Single Image Correlation. <i>Scientific Reports</i> , 2014, 4, 7341.	1.6	21
31	Animal Models of Hepatitis B and C. , 2014, , 44-49.		0
32	Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 1135-1138.	1.8	82
33	TIE2-expressing monocytes regulate revascularisation of the ischaemic limb. <i>Lancet, The</i> , 2013, 381, S78.	6.3	0
34	Bisphosphonates Target B Cells to Enhance Humoral Immune Responses. <i>Cell Reports</i> , 2013, 5, 323-330.	2.9	39
35	Effector CD8 T cell trafficking within the liver. <i>Molecular Immunology</i> , 2013, 55, 94-99.	1.0	29
36	Nkx2-5+Islet1+ Mesenchymal Precursors Generate Distinct Spleen Stromal Cell Subsets and Participate in Restoring Stromal Network Integrity. <i>Immunity</i> , 2013, 38, 782-791.	6.6	82

#	ARTICLE	IF	CITATIONS
37	TIE2-expressing monocytes/macrophages regulate revascularization of the ischemic limb. <i>EMBO Molecular Medicine</i> , 2013, 5, 858-869.	3.3	83
38	Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2165-72.	3.3	267
39	Follicular Helper NKT Cells Induce Limited B Cell Responses and Germinal Center Formation in the Absence of CD4+ T Cell Help. <i>Journal of Immunology</i> , 2012, 188, 3217-3222.	0.4	90
40	Kupffer Cells Hasten Resolution of Liver Immunopathology in Mouse Models of Viral Hepatitis. <i>PLoS Pathogens</i> , 2011, 7, e1002061.	2.1	96
41	Role of CCL2/MCP-1 in Islet Transplantation. <i>Cell Transplantation</i> , 2010, 19, 1031-1046.	1.2	69
42	Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. <i>Nature</i> , 2010, 465, 1079-1083.	13.7	309
43	Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection. <i>PLoS Pathogens</i> , 2010, 6, e1001227.	2.1	228
44	Modulation of Early Inflammatory Reactions to Promote Engraftment and Function of Transplanted Pancreatic Islets in Autoimmune Diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2010, 654, 725-747.	0.8	25
45	On the role of platelets in the pathogenesis of viral hepatitis. <i>Journal of Hepatology</i> , 2009, 51, 599-600.	1.8	16
46	Bone marrow as an alternative site for islet transplantation. <i>Blood</i> , 2009, 114, 4566-4574.	0.6	72
47	Tumor-Targeted Interferon- β Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis. <i>Cancer Cell</i> , 2008, 14, 299-311.	7.7	267
48	Platelets prevent IFN- β /IFN- γ -induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 629-634.	3.3	119
49	Antiplatelet Drug Therapy Moderates Immune-Mediated Liver Disease and Inhibits Viral Clearance in Mice Infected with a Replication-Deficient Adenovirus. <i>Vaccine Journal</i> , 2007, 14, 1532-1535.	3.2	56
50	Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. <i>Journal of Leukocyte Biology</i> , 2007, 81, 100-107.	1.5	120
51	In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. <i>Blood</i> , 2007, 109, 2797-2805.	0.6	168
52	HBV pathogenesis in animal models: Recent advances on the role of platelets. <i>Journal of Hepatology</i> , 2007, 46, 719-726.	1.8	84
53	IMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2006, 1, 23-61.	9.6	669
54	Reduced severity of liver ischemia/reperfusion injury following hepatic resection in humans is associated with enhanced intrahepatic expression of Th2 cytokines. <i>Hepatology Research</i> , 2006, 36, 20-26.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Defective Th1 Cytokine Gene Transcription in CD4+ and CD8+ T Cells from Wiskott-Aldrich Syndrome Patients. <i>Journal of Immunology</i> , 2006, 177, 7451-7461.	0.4	103
56	Pathogenetic and antiviral immune responses against hepatitis B virus. <i>Future Virology</i> , 2006, 1, 189-196.	0.9	17
57	Naive HIV/HCV-Coinfected Patients Have Higher Intrahepatic Pro-Inflammatory Cytokines than Coinfected Patients Treated with Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006, 11, 385-389.	0.6	13
58	Pathogenesis of Hepatitis B Virus in Transgenic Mice. , 2005, 25, 25-32.		1
59	Platelets mediate cytotoxic T lymphocyte-induced liver damage. <i>Nature Medicine</i> , 2005, 11, 1167-1169.	15.2	311
60	Immune Tolerance Split between Hepatitis B Virus Precore and Core Proteins. <i>Journal of Virology</i> , 2005, 79, 3016-3027.	1.5	194
61	Platelets Mediate Cytotoxic T Lymphocyte-Induced Liver Damage.. <i>Blood</i> , 2005, 106, 651-651.	0.6	0
62	A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14913-14918.	3.3	219
63	MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. <i>Journal of Clinical Investigation</i> , 2004, 113, 1158-1167.	3.9	106
64	MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. <i>Journal of Clinical Investigation</i> , 2004, 113, 1158-1167.	3.9	63
65	Searching for Interferon-Induced Genes That Inhibit Hepatitis B Virus Replication in Transgenic Mouse Hepatocytes. <i>Journal of Virology</i> , 2003, 77, 1227-1236.	1.5	108
66	Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13717-13722.	3.3	110
67	Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11181-11186.	3.3	183
68	Interleukin-18 Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice. <i>Journal of Virology</i> , 2002, 76, 10702-10707.	1.5	166
69	Activated Intrahepatic Antigen-Presenting Cells Inhibit Hepatitis B Virus Replication in the Liver of Transgenic Mice. <i>Journal of Immunology</i> , 2002, 169, 5188-5195.	0.4	109
70	Interferon-Regulated Pathways That Control Hepatitis B Virus Replication in Transgenic Mice. <i>Journal of Virology</i> , 2002, 76, 2617-2621.	1.5	112
71	The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection. <i>Vaccine</i> , 2002, 20, A80-A82.	1.7	47
72	NONCYTOLYTIC CONTROL OF VIRAL INFECTIONS BY THE INNATE AND ADAPTIVE IMMUNE RESPONSE. <i>Annual Review of Immunology</i> , 2001, 19, 65-91.	9.5	896

#	ARTICLE	IF	CITATIONS
73	Characterization of Nuclear RNases That Cleave Hepatitis B Virus RNA near the La Protein Binding Site. <i>Journal of Virology</i> , 2001, 75, 6874-6883.	1.5	53
74	Blocking Chemokine Responsive to β 2/Interferon (IFN)- β Inducible Protein and Monokine Induced by IFN- β Activity In Vivo Reduces the Pathogenetic but not the Antiviral Potential of Hepatitis B Virus-specific Cytotoxic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 2001, 194, 1755-1766.	4.2	225
75	Overcoming T Cell Tolerance to the Hepatitis B Virus Surface Antigen in Hepatitis B Virus-Transgenic Mice. <i>Journal of Immunology</i> , 2001, 166, 1389-1397.	0.4	73
76	Nuclear Covalently Closed Circular Viral Genomic DNA in the Liver of Hepatocyte Nuclear Factor 1 \pm -Null Hepatitis B Virus Transgenic Mice. <i>Journal of Virology</i> , 2001, 75, 2900-2911.	1.5	103
77	Cutting Edge: Inhibition of Hepatitis B Virus Replication by Activated NK T Cells Does Not Require Inflammatory Cell Recruitment to the Liver. <i>Journal of Immunology</i> , 2001, 167, 6701-6705.	0.4	102
78	Cytokine-Mediated Control of Viral Infections. <i>Virology</i> , 2000, 273, 221-227.	1.1	123
79	Inhibition of Hepatitis B Virus Replication during <i>Schistosoma mansoni</i> Infection in Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2000, 192, 289-294.	4.2	39
80	Host-Virus Interactions during Malaria Infection in Hepatitis B Virus Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2000, 192, 529-536.	4.2	61
81	Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo. <i>Journal of Experimental Medicine</i> , 2000, 192, 921-930.	4.2	560
82	Nitric Oxide Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2000, 191, 1247-1252.	4.2	117
83	Relative Sensitivity of Hepatitis B Virus and Other Hepatotropic Viruses to the Antiviral Effects of Cytokines. <i>Journal of Virology</i> , 2000, 74, 2255-2264.	1.5	238
84	Intrahepatic Induction of Alpha/Beta Interferon Eliminates Viral RNA-Containing Capsids in Hepatitis B Virus Transgenic Mice. <i>Journal of Virology</i> , 2000, 74, 4165-4173.	1.5	226
85	La Autoantigen Specifically Recognizes a Predicted Stem-Loop in Hepatitis B Virus RNA. <i>Journal of Virology</i> , 1999, 73, 5767-5776.	1.5	79
86	Noncytopathic Clearance of Lymphocytic Choriomeningitis Virus from the Hepatocyte. <i>Journal of Experimental Medicine</i> , 1999, 189, 1555-1564.	4.2	141
87	Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection. <i>Science</i> , 1999, 284, 825-829.	6.0	1,144
88	Cytokine-induced viral purging - role in viral pathogenesis. <i>Current Opinion in Microbiology</i> , 1999, 2, 388-391.	2.3	73
89	Hepatitis B Virus RNA-Binding Proteins Associated with Cytokine-Induced Clearance of Viral RNA from the Liver of Transgenic Mice. <i>Journal of Virology</i> , 1999, 73, 474-481.	1.5	91
90	In Vivo Regulation of Hepatitis B Virus Replication by Peroxisome Proliferators. <i>Journal of Virology</i> , 1999, 73, 10377-10386.	1.5	51

#	ARTICLE	IF	CITATIONS
91	Thymic Tolerance to Only One Viral Protein Reduces Lymphocytic Choriomeningitis Virus-Induced Immunopathology and Increases Survival in Perforin-Deficient Mice. <i>Journal of Virology</i> , 1999, 73, 5918-5925.	1.5	16
92	Mouse genetics at work: A new model of chronic hepadnavirus infection. <i>Hepatology</i> , 1998, 28, 268-269.	3.6	2
93	The optimization of helper T lymphocyte (HTL) function in vaccine development. <i>Immunologic Research</i> , 1998, 18, 79-92.	1.3	115
94	Immune Pathogenesis of Hepatocellular Carcinoma. <i>Journal of Experimental Medicine</i> , 1998, 188, 341-350.	4.2	354
95	Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice. <i>Journal of Virology</i> , 1998, 72, 2630-2637.	1.5	138
96	Hepatitis C virus core and E2 protein expression in transgenic mice. <i>Hepatology</i> , 1997, 25, 719-727.	3.6	133
97	Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes. <i>Immunity</i> , 1996, 4, 25-36.	6.6	1,065
98	Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 4589-4594.	3.3	196
99	Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant hepatitis. <i>Hepatology</i> , 1996, 24, 649-656.	3.6	32
100	To kill or to cure: options in host defense against viral infection. <i>Current Opinion in Immunology</i> , 1996, 8, 478-483.	2.4	257
101	The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. <i>Journal of Virology</i> , 1996, 70, 7056-7061.	1.5	113
102	Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 12398-12402.	3.3	123
103	Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 3764-3768.	3.3	416
104	Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. <i>Journal of Virology</i> , 1994, 68, 1265-1270.	1.5	133
105	Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice. <i>Journal of Virology</i> , 1994, 68, 5469-5475.	1.5	109
106	Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.. <i>Journal of Experimental Medicine</i> , 1993, 178, 1541-1554.	4.2	470
107	Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. <i>Journal of Virology</i> , 1993, 67, 7444-7449.	1.5	81
108	High-performance liquid chromatographic determination of d-amino acid oxidase activity. <i>Biomedical Applications</i> , 1991, 566, 377-382.	1.7	7

#	ARTICLE	IF	CITATIONS
109	A Derivatization Procedure Suitable for HPLC Analysis of Clenbuterol. Journal of Chromatographic Science, 1991, 29, 190-193.	0.7	14